TNF Dose Reduction Succeeds in PsA, Axial Spondyloarthritis
>
>
TNF Dose Reduction Succeeds in PsA, Axial Spondyloarthritis

TNF Dose Reduction Succeeds in PsA, Axial Spondyloarthritis

Patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) who were doing well on treatment with tumor necrosis factor (TNF) inhibitors were able to successfully taper the therapy when guided by disease activity.

Similarly, among patients with axSpA, the nonsignificant differences on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) were 0.03 (95% CI -0.21 to 0.27) during the taper period and 0.05 (95% CI -0.24 to 0.34) during the post-taper phase.

Treatment with TNF inhibitors has been demonstrated to be safe and effective in these disorders, but use of these medications can have drawbacks, such as an increased risk of infection and high costs

Read More: https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keab741/6380445

Share on

There are no comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Start typing and press Enter to search

Shopping Cart